APA
BMRN icon

American Portfolios Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

American Portfolios Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$35.9K Sell
423
-119
-22% -$10.6K ﹤0.01% 1897
2022
Q2 		$44.9K Buy
542
+11
+2% +$876 ﹤0.01% 1820
2022
Q1 		$40.9K Buy
531
+59
+13% +$4.94K ﹤0.01% 1981
2021
Q4 		$41.7K Sell
472
-60
-11% -$4.95K ﹤0.01% 1950
2021
Q3 		$41.1K Buy
532
+86
+19% +$6.79K ﹤0.01% 1881
2021
Q2 		$37.2K Buy
446
+31
+7% +$2.46K ﹤0.01% 1886
2021
Q1 		$31.3K Hold
415
– – ﹤0.01% 1824
2020
Q4 		$36.4K Buy
415
+72
+21% +$5.71K ﹤0.01% 1541
2020
Q3 		$26.1K Buy
343
+82
+31% +$8.3K ﹤0.01% 1581
2020
Q2 		$32.2K Sell
261
-6
-2% -$596 ﹤0.01% 1453
2020
Q1 		$22.6K Buy
267
+76
+40% +$6.55K ﹤0.01% 1485
2019
Q4 		$16.1K Buy
191
+34
+22% +$2.57K ﹤0.01% 1813
2019
Q3 		$10.6K Buy
157
+91
+138% +$7.01K ﹤0.01% 1911
2019
Q2 		$5.65K Buy
66
+21
+47% +$1.8K ﹤0.01% 2138
2019
Q1 		$4K Hold
45
– – ﹤0.01% 2170
2018
Q4 		$3.83K Buy
+45
New +$4.28K ﹤0.01% 1960

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

American Portfolios Advisors's BMRN Position: Q3 2022 in Review

American Portfolios Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 22% in Q3 2022, selling an estimated $10.6K and leaving 423 shares worth $35.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1897.

American Portfolios Advisors first reported a position in BMRN in Q4 2018 and has held it in 16 quarters since. The position peaked at $44.9K in Q2 2022. 552 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

  • American Portfolios Advisors held 423 shares of BioMarin Pharmaceuticals worth $35.9K as of Q3 2022.
  • American Portfolios Advisors sold 119 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $10.6K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #1897 holding.
  • American Portfolios Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2018 and has held it in 16 quarters since.
  • American Portfolios Advisors's BioMarin Pharmaceuticals position peaked at $44.9K in Q2 2022.
  • 552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.